<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01526941</url>
  </required_header>
  <id_info>
    <org_study_id>BIASP-1318</org_study_id>
    <nct_id>NCT01526941</nct_id>
  </id_info>
  <brief_title>Comparison of Single Dose and Steady State Pharmacodynamics of Biphasic Insulin Aspart 30 and 70 in Subjects With Type 1 Diabetes</brief_title>
  <official_title>A Double-blind, Randomised, Two-Period Crossover Trial Comparing the Single Dose and Steady State Pharmacodynamics of Biphasic Insulin Aspart 30 and Biphasic Insulin Aspart 70 in Subjects With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of this trial is to compare the single dose and
      steady state pharmacodynamics of biphasic insulin aspart 30 and biphasic insulin aspart 70 in
      subjects with type 1 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2001</start_date>
  <completion_date type="Actual">July 2001</completion_date>
  <primary_completion_date type="Actual">July 2001</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Steady state area under the glucose infusion rate profile, 6-12 hours</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>GIRmax, the maximal glucose infusion rate value</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax, time to maximum glucose infusion rate value</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>area under the glucose infusion rate profile</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to 50% of area under the glucose infusion rate profile, 0-12 hours</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax, maximum concentration</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax, time to reach Cmax</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tÂ½, terminal half-life</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Treatment period 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment period 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>biphasic insulin aspart 30</intervention_name>
    <description>Dose individually adjusted. Administered subcutaneously (s.c., under the skin) three times a day for 1 week in each treatment period. A wash-out period of 2-6 weeks will take place between treatment periods</description>
    <arm_group_label>Treatment period 1</arm_group_label>
    <arm_group_label>Treatment period 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>biphasic insulin aspart 70</intervention_name>
    <description>Dose individually adjusted. Administered subcutaneously (s.c., under the skin) three times a day for 1 week in each treatment period. A wash-out period of 2-6 weeks will take place between treatment periods</description>
    <arm_group_label>Treatment period 1</arm_group_label>
    <arm_group_label>Treatment period 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 diabetes for at least 12 months

          -  Currently on basal bolus treatment with soluble human insulin, Lispro and NPH insulin
             or Lantus. NPH insulin may be administered once or twice daily

          -  BMI (Body Mass Index) maximum 35 kg/m^2

          -  Able and willing to perform self-blood glucose monitoring

        Exclusion Criteria:

          -  The receipt of any investigational drug within the last 30 days prior to this trial

          -  Total daily insulin dose at least 1.8 U/kg/day

          -  Currently being treated with insulin aspart products

          -  A history of drug abuse or alcohol dependence within the last 5 years

          -  Impaired hepatic function

          -  Impaired renal function

          -  Blood donation (exceeding 500 ml) within the last nine weeks or haemoglobin below the
             lower reference limit according to the local laboratory

          -  Cardiac problems

          -  Severe, uncontrolled hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR,1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Neuss</city>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <results_reference>
    <citation>Bott S, Tusek C, Heinemann L, Friberg HH, Heise T. The pharmacokinetic and pharmacodynamic properties of biphasic insulin Aspart 70 (BIAsp 70) are significantly different from those of biphasic insulin Aspart 30 (BIAsp 30). Exp Clin Endocrinol Diabetes. 2005 Oct;113(9):545-50.</citation>
    <PMID>16235159</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2012</study_first_submitted>
  <study_first_submitted_qc>February 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2012</study_first_posted>
  <last_update_submitted>January 4, 2017</last_update_submitted>
  <last_update_submitted_qc>January 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
    <mesh_term>Insulin aspart, insulin aspart protamine drug combination 30:70</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
    <mesh_term>Biphasic Insulins</mesh_term>
    <mesh_term>Insulin, Isophane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

